| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 1,400 | 1,660 | 1,020 | 760 | 1,640 |
| Sales Growth | -15.66% | +62.75% | +34.21% | -53.66% | -22.27% |
| Net Income | -3,360 | -4,850 | -13,380 | -10,410 | -9,960 |
| Net Income Growth | +30.72% | +63.75% | -28.53% | -4.52% | +4.69% |
Yumanity Therapeutics Inc (YMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. The company's product candidate includes YTX-7739.Yumanity Therapeutics Inc., formerly known as Proteostasis Therapeutics Inc., is based in BOSTON.